IDEX Corporation — Q1 2024 Form 10-Q
Business and period: IDEX manufactures applied-solution products across Fluid & Metering Technologies (FMT), Health & Science Technologies (HST), and Fire & Safety/Diversified Products (FSDP). This unaudited report covers the three months ended March 31, 2024; comparisons are with Q1 2023 unless noted. All dollar amounts are in millions except per-share data.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $800.5 | $845.4 | -5%; organic sales -6% |
| Gross profit / margin | $357.4 / 44.6% | $382.5 / 45.2% | Profit -7%; margin -60 bps |
| Operating income | $161.2 | $192.3 | -16% |
| Net income attributable to IDEX | $121.4 | $139.8 | -13% |
| Diluted EPS attributable to IDEX | $1.60 | $1.84 | -13% |
| Adjusted net income / diluted EPS | $143.2 / $1.88 | $158.6 / $2.09 | -10% / -10% |
| Adjusted EBITDA / margin | $208.3 / 26.0% | $229.8 / 27.2% | -9% / -120 bps |
| Operating cash flow | $156.6 | $147.9 | +6% |
| Free cash flow | $136.6 | $121.3 | +13% |
Adjusted results and free cash flow are non-GAAP measures; the filing provides reconciliations. Q1 adjusted gross profit was $359.9 and adjusted gross margin was 45.0%, excluding a $2.5 STC inventory step-up charge.
Segments
- FMT: Sales $313.7, down 3%; Adjusted EBITDA $105.4, down 1%; margin 33.6%, up 60 bps. Lower industrial volumes were partly offset by pricing and productivity.
- HST: Sales $310.1, down 12% (organic down 13%); Adjusted EBITDA $81.4, down 19%; margin 26.2%, down 250 bps. Weakness in analytical instrumentation, life sciences, and semiconductor markets reflected inventory recalibration and ongoing market softness.
- FSDP: Sales $178.0, up 2%; Adjusted EBITDA $51.4, up 3%; margin 28.9%, up 40 bps. Pricing supported growth; volumes were flat.
Balance sheet, liquidity, and capital
- Cash and cash equivalents were $616.3 at March 31, 2024, versus $534.3 at year-end 2023. Working capital was $1,093.9 and the current ratio was 3.4 to 1.
- Total borrowings were $1,330.9, including $78.8 outstanding on the revolving facility. Revolver availability was $717.8, after $3.4 of letters of credit. The company reported compliance with debt covenants; leverage ratio was 1.49 to 1 and interest coverage was 18.48 to 1.
- Operating cash flow exceeded capital expenditures of $20.0; free cash flow was $136.6. Cash dividends paid were $48.5. No shares were repurchased; $539.7 remained authorized.
- International customers accounted for approximately 50% of sales. Cash held outside the U.S. was $475.0.
Changes, outlook, and notable items
- Consolidated sales fell 5%, primarily from lower volumes, with HST the main source of weakness. Management cited strong price/cost across segments. Gross margin also faced lower volume leverage and higher employee-related costs, partly offset by pricing and productivity.
- SG&A increased 3%, including acquisition impacts. Interest expense declined to $9.4 from $13.1, as lower debt and interest earned on cash more than offset higher borrowing rates.
- Recent acquisitions included Iridian (May 2023) and STC (December 2023); acquisitions net of divestitures added 1% to Q1 sales. The $2.5 STC inventory step-up charge and restructuring/impairment costs of $1.1 were notable items. Micropump and Novotema were divested in 2023.
- The effective tax rate was 21.5%, versus 22.2%, reflecting a discrete benefit from finalizing tax impacts of a prior legal-entity restructuring. Management does not expect a material impact from OECD Pillar Two rules based on its initial assessment.
- No quantified full-year 2024 revenue or earnings guidance is provided in the supplied filing text. Management said cash, operating cash flow, and available borrowing capacity are expected to fund operating needs, planned capital expenditures, debt service, benefit-plan funding, dividends, and potential repurchases for the foreseeable future; additional borrowing may fund suitable acquisitions.
- Risks highlighted include industrial and economic conditions, pricing and inflation, interest rates, capital spending, supply chains and labor, foreign exchange, tariffs and geopolitics, cybersecurity, acquisition integration, and litigation and environmental matters. Management reported no material change to previously disclosed risk factors or market risks.
- Ordinary-course legal matters are not expected by management to have a material adverse effect. Asbestos lawsuits remain pending; most resolved claims were dismissed without payment, and the company says insurance has covered most settlements and legal costs to date, but future insurance availability is uncertain.
Important facts for investors to verify
- Whether HST demand stabilizes after inventory recalibration and market softness, and how that affects organic sales and segment margins.
- How much of the decline in GAAP earnings reflects operating performance versus adjustments, particularly acquired-intangible amortization and the STC inventory step-up.
- Cash conversion sustainability, working-capital trends, and the company’s capital allocation among dividends, repurchases, acquisitions, and debt.
- Debt maturities, borrowing costs, covenant headroom, and the effect of foreign currency movements on reported results and equity.
- Developments in asbestos and other legal matters, including the availability of insurance coverage.